The genetic response to short-term interventions affecting cardiovascular function: Rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study - 09/08/11
, Patrick F. McArdle, PhD a, Haiqing Shen, PhD a, Evadnie Rampersaud, PhD a, Toni I. Pollin, PhD a, Lawrence F. Bielak, DDS, MPH b, Cashell Jaquish, PhD c, Julie A. Douglas, PhD d, Marie-Hélène Roy-Gagnon, PhD d, Paul Sack, MD a, Rosalie Naglieri, MD a, Scott Hines, MD a, Richard B. Horenstein, MD a, Yen-Pei C. Chang, PhD a, Wendy Post, MD, MS e, Kathleen A. Ryan, MPH a, Nga Hong Brereton, MS, RD a, Ruth E. Pakyz, BS, MT, ASCD a, John Sorkin, MD, PhD f, g, Coleen M. Damcott, PhD a, Jeffrey R. O'Connell, PhD a, Charles Mangano, BA, RDMS h, Mary Corretti, MD h, Robert Vogel, MD h, William Herzog, MD h, Matthew R. Weir, MD i, Patricia A. Peyser, PhD b, Alan R. Shuldiner, MD a, gRésumé |
Background |
The etiology of cardiovascular disease (CVD) is multifactorial. Efforts to identify genes influencing CVD risk have met with limited success to date, likely because of the small effect sizes of common CVD risk alleles and the presence of gene by gene and gene by environment interactions.
Methods |
The HAPI Heart Study was initiated in 2002 to measure the cardiovascular response to 4 short-term interventions affecting cardiovascular risk factors and to identify the genetic and environmental determinants of these responses. The measurements included blood pressure responses to the cold pressor stress test and to a high salt diet, triglyceride excursion in response to a high-fat challenge, and response in platelet aggregation to aspirin therapy.
Results |
The interventions were carried out in 868 relatively healthy Amish adults from large families. The heritabilities of selected response traits for each intervention ranged from 8% to 38%, suggesting that some of the variation associated with response to each intervention can be attributed to the additive effects of genes.
Conclusions |
Identifying these response genes may identify new mechanisms influencing CVD and may lead to individualized preventive strategies and improved early detection of high-risk individuals.
Le texte complet de cet article est disponible en PDF.Plan
| ☆ | This work was supported by the NIH Institutional Training Grant in Cardiac and Vascular Cell Biology (T32HL072751) and by grant U01 HL72515, the University of Maryland General Clinical Research Center (GCRC) (M01 RR 16500), the Johns Hopkins University GCRC (M01 RR 000052), National Center for Research Resources, the Clinical Nutrition Research Unit of Maryland (P30 DK072488), and the Paul Beeson Physician Faculty Scholars in Aging Program of the American Federation of Aging Research. |
Vol 155 - N° 5
P. 823-828 - mai 2008 Retour au numéro
Article précédent
- Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III)
- Anne M. Belonje, Adriaan A. Voors, Wiek H. van Gilst, Stefan D. Anker, Riemer H. Slart, Rene A. Tio, Felix Zijlstra, Dirk J. van Veldhuisen, on behalf of the HEBE III investigators
- Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005
- Kevin Jackson, Bernard J. Gersh, Norman Stockbridge, Thomas R. Fleming, Robert Temple, Robert M. Califf, Stuart J. Connolly, Lars Wallentin, Christopher B. Granger, Participants in the Duke Clinical Research Institute/American Heart Journal Expert Meeting on Antithrombotic Drug Development for Atrial Fibrillation
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?